Overview

TMC435350-TiDP16-C101 - A Study to Examine the Safety, Tolerability and Pharmacokinetics of Increasing Oral Doses of TMC435350 After Single and Repeated Dosing

Status:
Completed

Trial end date:
2007-09-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to examine the safety, tolerability and pharmacokinetics of increasing oral doses of TMC435350 after single and repeated dosing, followed by an open label repeated dosing session in 6 HCV genotype1 infected patients.

Phase:

Phase 1

Details

Lead Sponsor:

Tibotec Pharmaceuticals, Ireland

Treatments:

Simeprevir